Title: Preclinical validation of electrochemotherapy as an effective treatment for brain tumors

Authors: Birgit Agerholm-Larsen\textsuperscript{1,2,3}, Helle K. Iversen\textsuperscript{2,3,4}, Per Ibsen\textsuperscript{5}, Jakob M. Moller\textsuperscript{6}, Faisal Mahmood\textsuperscript{1,3}, Kurt Svarre Jensen\textsuperscript{1,2,3}, Julie Gehl\textsuperscript{1,3}

Affiliation: \textsuperscript{1}Department of Oncology, Copenhagen University Hospital Herlev, \textsuperscript{2}Glostrup Research Institute, Copenhagen University Hospital Glostrup, \textsuperscript{3}Center for Experimental Drug and Gene Electrotransfer (C*EDGE), Copenhagen University Hospital Herlev, \textsuperscript{4}Department of Neurology, Copenhagen University Hospital Glostrup, \textsuperscript{5}Department of Pathology, Copenhagen University Hospital Herlev and Hvidovre, \textsuperscript{6}Department of Radiology, Copenhagen University Hospital Herlev, Denmark.\textsuperscript{1}

Running title: Electrochemotherapy for Brain Tumors.

Key Words: Electrochemotherapy, Electroporation, Brain Tumor, Electrodes, Bleomycin

Grant Support: The Danish National Advanced Technology Foundation (J. Gehl, H.K. Iversen), Copenhagen County Foundation (J. Gehl, H.K. Iversen), and Einar Willumsens Foundation (B. Agerholm-Larsen, J. Gehl). J. Gehl is a Royal Swedish Academy of Sciences Research Fellow supported by a grant from the Acta Oncologica Foundation. Corresponding Author: Julie Gehl, Copenhagen University Hospital Herlev, Department of Oncology, 54B1, Herlev Ringvej 75, DK-2730 Herlev, Denmark, E-mail: juge@heh.regionh.dk

Conflict of interest: J.G., F.M. and B.A.-L. have patents granted or pending related to this work.
Abstract

Electrochemotherapy represents a strategy to enhance chemotherapeutic drug uptake by delivering electric pulses which exceed the dielectric strength of the cell membrane, causing transient formation of structures that enhance permeabilization. Here we show that brain tumors in a rat model can be eliminated by electrochemotherapy using a novel electrode device developed for use in the brain. Using this method, the cytotoxicity of bleomycin can be augmented >300-fold due to increased permeabilization and more direct passage of drug to the cytosol, enabling highly efficient local tumor treatment. Bleomycin was injected intracranially into male rats inoculated with rat glia-derived tumor cells two weeks prior to the application of the electric field (32 pulses, 100V, 0.1 ms, 1 Hz). In this model, where presence of tumor was confirmed by MRI before treatment, we found that 9/13 rats (69%) receiving electrochemotherapy displayed a complete elimination of tumor, in contrast to control rats treated with bleomycin only, pulses only or untreated where tumor progression occurred in each case. Necrosis induced by electrochemotherapy was restricted to the treated area, which MRI and histology showed to contain a fluid-filled cavity. In a long-range survival study, treatment side effects appeared to be minimal, with normal rat behavior observed after electrochemotherapy. Our findings suggest that electrochemotherapy may offer a safe and effective new tool to treat primary brain tumors and brain metastases.
Electrochemotherapy for Brain Tumors

**Introduction**

Primary and secondary malignant tumors of the brain constitute a significant challenge in cancer treatment. Surgery, radiotherapy and medical treatment is advancing, but the prognosis is still grim and morbidity considerable (1, 2).

Electroporation based treatments may be a new contributor in inhibiting tumor recurrence, whilst giving rise to limited side-effects (3-7). Electroporation - permeabilization of membranes by electric pulses - has become an expanding research field, both within nonthermal irreversible electroporation from which cell membranes do not recover and cell death ensues (3, 4, 7-9), and within reversible electroporation where cell membranes do reseal and only transiently allowing drugs (10, 11) or genes (12-20) to enter the otherwise intact cell.

Electrochemotherapy designates the use of electroporation to enhance local uptake of chemotherapeutic agents (21-24), enabling an increase in cytotoxicity of a staggering 300 fold in the case of bleomycin. What is well known is that electrochemotherapy with its high efficiency may be used as a once-only treatment, and that no treated cancer histology has yet been unresponsive to the treatment (25). Both these factors are an advantage for tumors in internal organs, including intracranial tumors. Electroporation based treatments in internal organs are ongoing (www.clinicaltrials.gov), (26, 27).

Bleomycin is well known in oncology, and is used in standard treatment regimens for e.g. testicular cancer (28), and intracerebral use is well described (29). The choice of bleomycin as the cytotoxic agent for electrochemotherapy is previously described (5, 6, 22, 25, 30-32) and has a solid scientific base; thus bleomycin acts as an enzyme creating 10-15 DNA strand breaks per molecule (33), which is a far more efficient rate than any other chemotherapeutic agent. Bleomycin is large, charged and hydrophilic and the cell membrane will under normal circumstances keep it from the actual target of the drug, namely DNA. Electroporation offers direct access over the cell
Electrochemotherapy for Brain Tumors

membrane in the area encompassed by the electrodes, allowing bleomycin to exert its cytotoxic potential much more efficiently. Bleomycin as single drug has been tried in the treatment of brain tumors before, with acceptable toxicity but limited efficacy (29). Only one previous study by Salford et al (34) investigated the use of reversible electroporation in a rat brain tumor model facilitating the uptake of bleomycin (electrochemotherapy) using two acupuncture needles inserted into rat brains inoculated with tumor cells. In this study survival was improved by a few days, however, the electric field between two single needles is of limited extension.

We have now developed an electrode device, which can be inserted through a single burr-hole, with electrodes that may be subsequently deployed in a cone shaped formation to treat a target area much larger than the burr hole. Electrochemotherapy, encompassing intracranial injection of bleomycin followed by pulses, was performed in normal and tumor bearing rats in short and long term studies, using this novel brain electroporation device to explore electrochemotherapy as a new treatment modality for brain tumors.
Materials and Methods

Study design

Three experimental designs, each conducted through 2-4 independent experiments, were performed in rats.

Experimental setup # 1 (n=60) – finding appropriate brain electrodes and parameters for electrochemotherapy in the rat brain: Tumor cells were inoculated in the rat brain, and after 1-2-weeks electrochemotherapy, electroporation only, bleomycin only, or NaCl were injected followed by electroporation using respectively a 4- or 8-electrode device. After treatment MRI was performed repeatedly and animals were observed for 1½ weeks.

Experimental setup # 2 (n=25) – could electrochemotherapy eliminate rat brain tumors; Tumor cells were inoculated and only after MRI verification of tumor, rats were treated by electrochemotherapy, electroporation alone or bleomycin alone using the 8-electrode device. After treatment MRI was performed repeatedly and the animals were observed for up to 3 weeks, with prior termination if symptoms or MRI indicated too large tumor size.

Experimental setup # 3 (n=15) – what is the long term effect of electrochemotherapy in the rat brain: The long term effects of electrochemotherapy by the 8-electrode device in healthy brain tissue were studied with repeated MRI, and observation for eight weeks.

Animals

Male rats (Fischer (F344/SCA),Scanbur AB, Sweden (# 1) and Sprague Dawley (SD), Taconic, Denmark (# 2 and # 3), 7-11 months old were and kept at Glostrup Research Institute. Protocol was approved by The Danish Animal Experiments Inspectorate.

Anesthesia for surgery or MR scanning was by s.c. injection of Hypnorm (VetaPharma Ltd., United Kingdom) with Midazolam (Hameln Pharmaceuticals GmbH, Germany)
or Dormicum (Roche, F. Hoffmann-La Roche AG, Schweiz). Analgesia was administered twice over 48 hours with Rimadyl (50mg/mL, Pfizer Aps., Denmark).

**Inoculation of N32 glioma derived cells**

N32 cells were kindly provided in 2008 by Leif Salford, Lund University, Sweden (35), were maintained and prepared as previously described (36), and tested by rapid MAP-27 panel (Taconic, Denmark), last in November 2010 without signs of infection. The N32 rat glioma cells have been shown to grow readily in *in vitro* systems, as well as intracerebrally to develop tumors, and is only weakly immunogenic (35). Cell culture sample from stock solution was prepared 2-3 weeks before inoculation and 3000 N32 cells were inoculated (5μL). The skull area around bregma was accessed with scalpel and a burr hole (5 mm diameter) made by trepan drill. Injection was at 4 mm depth at the stereotaxic coordinates X=2, Y=1, Z=-4 (Kopf 962 Dual Ultra Precise Small Animal Stereotaxic Instrument). Micrometer positioning ensured gentle needle passage (Neoflon 24GA or Spinal Needle 27GA, Becton & Dickinson) into the brain tissue, and a pump (Univentor U-802 Syringe Pump, AgnTho’s AB, Sweden) was used to inject cells. The burr hole was covered by bone wax (B|Braun, Germany) and the skin sutured.

**Electrochemotherapy**

In Experimental setup # 1 an initial prototype with only 4-electrodes as well as an improved 8-electrode device were developed (Sonion A/S, Roskilde, Denmark) (Figure 1), after this only the 8-electrode device was used. Electrochemotherapy was performed by initial intracranial injection of 42 IU of bleomycin contained in 14μL (freeze dried 15000 IU Bleomycin, Baxter A/S, dissolved in 5 mL isotonic NaCl) (X=2, Y=1, Z=-4), using a pump, and leaving the needle in the tissue for 5 min before retraction. The 8-electrode device was deployed through the burr hole to treatment depth at 5 mm (X=2, Y=1, Z=-5), and 32 pulses (4 x 8 pulses) (Figure 1), each of 100V,
Electrochemotherapy for Brain Tumors

0.1 ms duration, 1Hz were applied. This electrode gave rise to an electric field of at least 280 V/cm in an area of 100 mm³. The 4-electrode device was used for 8 pulses (Figure 1). Pulses were delivered by a square pulse generator (Cliniporator, IGEA, Italy) and polarity of the electrodes was switched after each pulse using a switch box (Sonion A/S, Roskilde, Denmark). All treatments were performed as “once-only” in each rat, and no rats received more than one treatment modality.

**MRI**

A human 3 Tesla Magnetic Resonance Imaging (MRI) system was used (Achieva, Philips, The Netherlands). The head of the sedated rat was placed in a 50 mm 4 channel phased array animal coil (Animal Coil, Shanghai Chenguang Medical Technologies, China). Both T2 weighted turbo spin echo sequences (TR/TE: 4847/100, FOV/matrix: 50/248, 1 mm slices and scan time: 5:58 min), and T1 weighted sagittal gradient echo sequences (TR/TE/FA: 31/10/30, FOV/matrix: 50/500, 1 mm slices and scan time 7:21 min) before and after intravenous contrast agent administration by tailvein (0.3 mmol/kg Dotarem, Guerbet, France) were performed, supplemented by a post contrast transverse T1 weighted gradient echo (TR/TE/FA: 31/10/30, FOV/matrix: 50/625, 1 mm slices, scan time 13:37 min.). Blankets and heating pads were used.

**Tumor volume**

From the MR scans volume of tumor alone (before treatment), or the combination of tumor and tissue in vicinity reactive to treatment were approximated by in one plane measuring the longest diameter \((a)\) and the longest diameter \((b)\) perpendicular to \(a\) by Achieva scan software 2.6.3.3, Philips Healthcare. Tumor volume was calculated as \(V = \frac{1}{6}a^2b\pi\).
Electrochemotherapy for Brain Tumors

**Termination**

Rats were terminated by anesthesia followed by lethal pentobarbital injection. Animals were perfused with isotonic NaCl followed by 4% para-formaldehyde and kept at 5ºC for at least 24 hours before further procedures.

**Histology**

H&E, PAS and immunohistochemical staining were according to standard protocols. Immunohistochemical staining of neurofilaments (NF) with Monoclonal Mouse Anti-Human, 2F11 (Dako, Denmark) and for glial filament (GFAP) Polyclonal Rabbit Anti-GFAP (Dako, Denmark). The following characteristics were listed and graded by an experienced pathologist, blinded with respect to treatment status: presence of 1) tumor or tumor cells, 2) necrotic tissue, 3) macrophages, 4) erythrocyte traces, and 5) condensed or lacking neurofilaments or glial filaments immunohistochemical staining, all graded 0-3. The score 0 was given for normal situation whereas 3 indicated highly abnormal situation in the area of interest. We used an Olympus Bx50 microscope (Olympus lenses, plan objective x2), Olympus Color View 1 Camera (tubus, UTV, 0.5xG3), and Olympus Soft Imaging System (analySIS getIT, Olympus, Denmark).

**Statistics**

Log-rank (Mantel-Cox) Test was used for survival curve comparison, t-test for the tumor volume measurement and Mann-Whitney U-test was used for statistical handling of the pathologic scores. P-values less than 0.05 were considered statistically significant on a two-sided scale.
Results

Brain tumor response to treatment

Electrochemotherapy induced regression and elimination of tumor in the targeted brain areas in 9 of 13 rats over 2-3 weeks, whereas 8 control rats all showed tumor progression as illustrated in Figure 2 (Experimental setup #2 using the 8-electrode device), where tumor volume measured on MRI are shown (panel A) along with a survival curve (panel B) indicating when rats were euthanized due to large tumor size. Tumors were verified before treatment by MRI and had a mean size of 7 mm$^3$ (range 1-34).

Immediately after electrochemotherapy or electroporation and lasting for up till one week, treatment effects appeared as similar sized areas (low SEM) with a diffused transition zone between contrast and non-contrast enhanced brain tissue. Images from six consecutive MR scans of a rat that had received electrochemotherapy are shown in Figure 3. In general we observed that this short term treatment effect on contrast enhancement is not clearly distinguishable from contrast enhancement reflecting a tumor, and the measurements listed in Figure 2A include the entire contrast enhancement observed.

Among the thirteen rats treated with electrochemotherapy, nine rats (69%) showed regression of tumor and then no tumor, and four rats (31%) showed tumor progression. Of these four rats showing progression one rat had tumor cell remains outside the treatment target area, and three rats were characterized by having the three largest initial tumors prior to treatment. There were eight rats in the control treatment group, represented by untreated rats (n=4), rats treated with electroporation only (n=2), or with bleomycin only (n=2). All control rats had statistical significant increased tumor size (contrast enhancement) already within 1 week after tumor appeared on MRI (p<0.01), as well as after 2 weeks (p<0.01), compared to rats given electrochemotherapy; control rats all needed to be terminated prior to end of experiment due to tumor progression, and none
showed any sign of treatment effect. The statistical tests are based on results including treatment effect seen within the first week. The Kaplan-Meier survival curve (Figure 2B) reflects termination due to tumor progression, and the difference between the two groups was significant (p<0.001).

Rats were only included if they had a verified tumor on MRI. Later exclusion criteria were i) odd growing tumor located near surface (one rat), histological confirmed fibrotic tissue showing contrast enhancement similar to tumor (one rat), small tumors on MRI not later confirmed (two rats).

Histological analyses showed consistency with the end stage MRI verified presence or absence of tumors (Figure 4). The initial sizes of the tumors are similar for the two rats in Figure 4, but the rat receiving electrochemotherapy had no tumor or tumor cell remains at termination (30 days). The rat receiving electroporation only had a tumor with characteristics also seen in human glioblastoma multiforme (intratumoral necrosis, pseudo palisading necrosis) at termination (24 days).

All in all, 9 of 13 rats (69%), with MR verified tumor, given electrochemotherapy, had no tumor upon termination, and all of 8 rats receiving either no treatment (n=4), bleomycin (n=2) or pulses only (n=2) had tumor progression and early termination was necessary.

**Rat brain tissue reactions to treatment**

In Experimental setup # 1 the effect of electrochemotherapy for the initial 4-electrode device prototype and the improved 8-electrode device showed dose response, with the 8-electrode device having the highest impact on brain tissue both visually (Figure 5) and quantitatively (Figure 6). Electrochemotherapy is characterized by impacting rat brain tissue in the targeted area only (Figure 5) corresponding to and restricted by the electric field distribution (Figure 1). The 8-electrode device is significantly superior to the 4-electrode device showing more severe morphological changes with extensive necrosis, macrophage invasion, bleeding spots, loss of
neurons and astrocytes (represented by their filaments), and no presence of tumors or tumor cell remains shown by H&E, NF and GFAP staining (Figure 6). These effects of electrochemotherapy are easily distinguishable from brain tissue reaction to plain electroporation, bleomycin or NaCl, where only macrophage invasion could match the effect found at electrochemotherapy, except for bleomycin which also showed moderate impact on astrocytes (Figure 5 and 6).

**Long term effect of electrochemotherapy in healthy rat brain tissue**

Experimental setup # 3 pursued the long term effect of electrochemotherapy (n=8), bleomycin or electroporation (n=7) in healthy rat brain tissue, with no prior inoculation of tumor cells. We found no long term effect of either bleomycin or electroporation. For the rats treated with electrochemotherapy repeated MRI (data not shown) suggests an ongoing process towards increased tissue degradation and increased presence of tissue fluid other than blood (e.g. cerebrospinal fluid) in the treated area at *in vivo* follow-up by MRI for 8 weeks. The targeted area gradually lost contrast enhancement and gradually increased appearance of dark areas (on T1 weighted scans) suggesting an emerging fluid filled space, as illustrated in Figure 7 (A1 and B1). At termination these brains all appeared with substantial loss of tissue in targeted areas. Histological analyses showed healthy brain tissue in proximity to clearly distinguishable cavities at the location of the targeted area of the brain for all eight rats after electrochemotherapy (Figure 7, A2 and B2). We found no histological evidence of remains of necrotic cells or bleeding, but occasionally presence of very few macrophages in bordering healthy tissue. Histological analyses of control rats showed no sign of cavity formations, but minor traces after intrusion with intracranially bleomycin injection were observed.
Electrochemotherapy for Brain Tumors

**Tolerability**

Based on our records from pilot project as well as from the reported experiments the anesthesia and analgesia were in general well tolerated by the rats. Incidence of rupture of superior sagittal sinus during the surgical procedure (drilling) was <5%. All rats recovering from analgesia regained normal rat behavior within 48 hours with no observed characteristic or adverse behavior related to treatment status. Post-treatment mortality was observed in <1% of the treated rats. Long term effect of electrochemotherapy revealed loss of tissue corresponding to the targeted area, but basic normal rat behaviors were maintained until termination date. We did not observe any obvious difference in basic behavior between rats receiving different treatments in the short term studies. Specifically, no abnormalities in terms of motor function or behavior were observed, and the treated and control groups responded similarly to sedation and experimental procedures.
Electrochemotherapy for Brain Tumors

Discussion

The use of electric pulses to create transient permeabilization in the cell membrane (electroporation) is well characterized (21, 23, 24), and so is the combination with a cytotoxic agent to enhance the efficacy of this agent by creating direct access to the cell cytosol (5, 6, 12, 22, 25, 30-32). This study is the first report of electrochemotherapy of experimental brain tumors in rats with a novel expandable electrode, and we have shown that this treatment method is highly effective with complete resolution of 69% of treated tumors after once-only treatment. Furthermore, treatment effects are localized to the target area, and that the toxicity profile is favorable, with no apparent influence on rat behavior or morbidity.

A grim prognosis and substantial morbidity continues to be associated with both primary and secondary (metastatic) brain tumors (1, 2). From previous experience with electrochemotherapy of superficial tumors (5, 6, 25, 30, 32), it is known that this treatment modality has proven highly efficient regardless of tumor histology and as a once-only treatment also after previous radio- or chemotherapy (25)Domenge, 1996 28 /id;Matthiessen, 2011 4285 /id;Sersa, 2011 4284 /id}. Furthermore, electric pulses may be delivered in a few seconds, enabling intraoperative treatment. We therefore decided to test a novel electrode device for electroporation of brain tumors, in the hope that the encouraging preclinical results in this study could be translated to treatment of primary and secondary brain tumors in the clinic.

Development of electrodes

Only one previous study reports the use of electrochemotherapy in an animal model of brain cancer, dating back to 1993 (34). Here, the investigators used two opposing acupuncture needles to apply the electric field, giving rise to a rather small treatment area. In this study, we have tested an electrode which may enter through a burr hole and expand to cover an area larger than the
Electrochemotherapy for Brain Tumors

insertion (38, 39). Furthermore, pulse sequencing has been developed, to ensure sufficient coverage of the treatment area (Figure 1).

**Electrochemotherapy of brain tumors**

Having the electrode device it was possible to move on to the first and fundamental question: *Does the electrode device work?* In experimental setup #1, a 4- and an 8-electrode device were tested, and it was found that areas of necrosis after electrochemotherapy corresponded to the configuration of the two electrode devices. Furthermore, that the combination of drug and pulses gave rise to necrosis in the treatment area whereas only pulses or only drug did not, as previously described (40, 41).

The second very important question was; *can we determine presence of established tumors on MRI before treatment, and what is the success rate of electrochemotherapy when macroscopic tumors are present?* We found that tumors could be seen on MRI, but also that we could see the overlay of the treatment area as an extended zone of contrast enhancement around the tumor itself. The initial increase in volume, also for tumors that later disappeared, could be caused by a treatment related effect around the tumor. We could not distinguish the boundary between the actual tumor and treatment effects on MRI, however the latter subsided within a week. Recent research indicates that in the future diffusion weighted MRI may give additional information on the treatment volume (42).

The complete disappearance of 69% of treated tumors was highly encouraging, but not necessarily unexpected. Thus, in the treatment of cutaneous tumors complete remission rates have been reported to be between 60 and 90% (25, 41, 43). In our animal model we treated an area around 100 mm$^3$ and observed a 69% remission. It has been shown that in larger tumors the success rate is lower (43), in concordance with the fact that every part of the tumor must be covered by the electric field to achieve success (42, 44-46). It is noteworthy that 3 of the 4 rats that were not
successfully treated in the study had the largest tumors when treated, indicating that it is likely that the success rate is very high when the tumor is encompassed by the electrode. The electrode used in this study is a prototype for use in rats, and it was only placed once. We are anticipating use of an electrode device for treatment in humans, but this will be with a larger electrode device (38), that may be sequentially deployed to cover a larger tumor volume.

A third, and very important question has been; is brain electrochemotherapy safe? In order to investigate this question, healthy rats were subjected to electrochemotherapy. By not inoculating with brain tumor cells, possible interference from tumor growth could be avoided. MR scans as well as behavioral assessments were performed, as well as histology at the end of the observation period.

Again it was found that histological sections revealed far more pronounced effects after electrochemotherapy than after pulses or drug alone. This was also evident from MR scans, and as an example shown in Figure 7 reveals, the treatment area is subjected to necrosis and subsequent resolution, after which a fluid filled cavity appears, not unlike radiological findings after stroke.

The behavioral observations included basic motor ability and orientation behavior (i.e. neurological dysfunction, hemiparesis), and no obvious effects on these were found, despite the marked findings on MRI. Although treatment related effects were present at MRI (see Figure 3), this did not seem to affect rat behavior, probably because it was limited to part of the brain.

What is known from previous studies on electrochemotherapy using bleomycin is that the number of molecules internalized may influence the type of cell death that ensues (33). A window of opportunity exists where normal tissue may be spared whereas tumor tissue will be severely affected (25). In this paper, intratumoral injections of bleomycin have been performed, which tends to give a high number of molecules internalized, leading to necrosis of both tumor
Electrochemotherapy for Brain Tumors

tissue and normal tissue (47). From clinical studies we know that normal tissue may be spared whilst efficient tumor cell kill is obtained when intravenous administration is used (25), because intravenous administration gives a lower and more evenly distributed tissue dose, and this may allow treatment within a therapeutic window. Further experiments on lowering bleomycin tissue dose, including intravenous administration, may further elucidate the question of how to obtain complete tumor regression whilst preserving normal tissue in the brain.

Several studies have documented an anti-vascular effect of both electric pulses and the combination of electric pulses and bleomycin (electrochemotherapy) (3, 48). Thus, in addition to electric pulses affecting perfusion and endothelial cells, bleomycin also has known activity against endothelial cells and has been used in treatment of vascular malformations (49). This antivascular effect may in fact be very important in the tumor response seen with both irreversible electroporation and electrochemotherapy (3, 4, 8, 48, 50).

Recently published studies on irreversible electroporation (3, 4, 7-9) have shown encouraging results in tumor treatment in canine models, as well as evidence of normal tissue preservation (9). When combining electric pulses with bleomycin a lower field strength can be used, as shown in this study. The overall, and highly encouraging conclusion, is that a novel treatment paradigm using electric pulses in cancer treatment may lead to efficient ablation with limited side effects, and that further research may expand the use of this technology even further.

An electroporation device has been developed for the clinic, namely a 13-electrode device which will be able to encompass a larger treatment area (www.clinicaltrials.gov), (42).

Potential side effects to electrochemotherapy in the human brain encompass risk of anesthetic complication, hemorrhage and infection. Relaxation to prevent peripheral motor response during the electrochemotherapy procedure and general anesthesia will be necessary. However, the electrochemotherapy procedure can be short as the electric pulses are quickly delivered. Edema will
ensue, but focally where the electrochemotherapy has been performed, as has indeed been seen at the MRI studies in the present paper. Steroids may ameliorate edema.

**In conclusion**

The data presented here is the first study on brain electrochemotherapy using an expandable electrode device, enabling treatment of larger brain tumors through a burr hole. Results are highly encouraging, showing a high level of efficacy with a 69% complete response rate and limited toxicity. The results are similar to what has been shown in clinical trials of electrochemotherapy of skin metastases, and this would lead to optimism regarding the possibilities for electrochemotherapy to be of benefit to patients suffering from primary or secondary cancers of the brain.

**Acknowledgement**

Leif Salford, Lund University Hospital, Sweden, is thanked for providing the N32 tumor cells. We also would like to acknowledge skilful technical assistance from Birgit Hertz, Lone Bojesen and the Technical Team at Sonion.
Electrochemotherapy for Brain Tumors

References


Electrochemotherapy for Brain Tumors


Electrochemotherapy for Brain Tumors


Electrochemotherapy for Brain Tumors

(30) Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM.


Electrochemotherapy for Brain Tumors


Electrochemotherapy for Brain Tumors


Electrochemotherapy for Brain Tumors


Figure legends

Figure 1. A 4- (A) respectively 8-electrode device (B) for use in rat brain tissue. The 4 electrodes in the 4-electrode device will go straight forward when deployed in the brain tissue. When the 8-electrode device is deployed in the brain the outer 4 electrodes will create a cone shape, whereas the inner 4 electrodes will go straight forward. Electric field distributions (V/cm) (C) shown as central slice plots perpendicular to the electrodes; white and black circles correspond to different potentials. Each window is 5x5 mm. Electric field distribution is shown for a 2-, 4-, and an 8-electrode device at a particular polarity pattern (100 volt applied). For the 8-electrode device each pulse consists of 4 polarity patterns, such that each is rotated 90° compared to the previous, to complete a full revolution.

Figure 2. Tumor volume estimated as contrast enhanced area of tumor and brain tissue reaction to treatment if present, mean ± SEM (A), and Kaplan-Meier plot showing survival in percentage (B), both as a function of days; Day -1 = MRI confirmed rat brain tumor. Closed circle (●) and solid line (—) designates electrochemotherapy, n=13 animals. Open circle (○) and dotted line (---) designates electroporation, bleomycin or no treatment, n=8 animals. Numbers in parenthesis indicate animals investigated at that particular time point; discrepancies between numbers in (A) and (B) reflect availability of MRI. Electrochemotherapy = Electric pulses in the presence of bleomycin, with the aim of enhanced bleomycin uptake.

Figure 3. Magnetic resonance imaging (MRI) of a rat brain (T1 weighted after injection of contrast). Illustrations show craniocaudal MR scans in a dorsoventral orientation. Day -1: Appearance of a rat brain tumor (contrast enhancement) 12 days after inoculation of N32 rat glial derived tumor cells.
Electrochemotherapy for Brain Tumors

Day 1: The day after electrochemotherapy, contrast enhancement of tumor overlaid with tissue reaction to electrochemotherapy. Day 7, 9, 15 and 21 shown in following panels as indicated. Electrochemotherapy = Electric pulses in the presence of bleomycin, with the aim of enhanced bleomycin uptake.

Figure 4. Electrochemotherapy versus electroporation alone. Left: MRI of two rats at the time point for confirmation of presence of similar sized tumors prior to treatment. Right: Pathological H&E staining showing the development respectively resolution of the tumor at the end of the experiment for a rat given electroporation (EP) (top) and electrochemotherapy (ECT) (bottom). MRI show craniocaudal scans in dorsoventral orientation. Electrochemotherapy = Electric pulses in the presence of bleomycin, with the aim of enhanced bleomycin uptake.

Figure 5. Paraformaldehyde perfused rat brains stained with H&E (left column), NF (middle column) and GFAP (right column). Treated groups were; ECT (Electrochemotherapy i.e. bleomycin and electroporation) using either the 4-or 8-electrode device. Controls were EP (just pulses), bleomycin injection only, and saline injection. Original magnification, x20; bars, 1mm.

Figure 6: Median scores of observed changes in brain tissue on histological sections as a function of treatment with various solutions, devices and electroporation parameters. Upper panel (A); neurofilaments (white) and glial filaments (black). Lower panel (B); necrotic cells with (light-gray) and without cavity (gray), trace of erythrocytes (middle-gray) and macrophages (dark-gray). 0=not present, 1= just present or only few, 2= clearly present, and 3=extensively present. All inoculated with N32 tumor cells except for those treated with NaCl. Bleomycin was injected intracranially. Mann-Whitney U-test (two-sided) with ECT (8-elec, 8x4) as reference, *=p<0.05, **=p<0.01, and
Electrochemotherapy for Brain Tumors

***=p<0.001. ECT = Electrochemotherapy = Electric pulses in the presence of bleomycin, with the aim of enhanced bleomycin uptake. EP = electroporation. NaCl = sodium chloride. “4-elec, 8” = 4-electrode device, 8 pulses. “8-elec, 8x4” = 8-electrode device, 8x4 pulses.

Figure 7: Long term effect of electrochemotherapy using intratumoral bleomycin injection, in healthy rat brain tissue. Illustrations of two rats (A and B), both receiving electrochemotherapy. T1 weighted contrast enhanced MRI (top, craniocaudal scans in a dorsoventral orientation) and H&E staining (bottom). Eight weeks after electrochemotherapy loss of contrast enhancement was observed in the targeted areas in exchange for evidence of fluid filled cavities (A1 and B1 dark areas). Histological analyses revealed cavities in the targeted areas (A2 and B2).

Electrochemotherapy = Electric pulses in the presence of bleomycin, with the aim of enhanced bleomycin uptake.
Figure 2

(A) Tumor Volume (mm$^3$) over Time post treatment (days).

(B) Percent Survival over Time post treatment (days).

Legend:
- (21) (13)
- (4) (8)
- (0) (7)
- (5) (10)
- (9) (3)
- (8) (2)
Figure 5
Figure 7
Preclinical validation of electrochemotherapy as an effective treatment for brain tumors

Birgit Agerholm-Larsen, Helle K Iversen, Per Ibsen, et al.

Cancer Res  Published OnlineFirst April 20, 2011.

Updated version

Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-11-0451

Author Manuscript

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.